Sanofi India Reports Q4 FY26 Financial Results; Net Profit at ₹1,026 Million
Sanofi India Limited has reported its financial results for the quarter ended March 31, 2026, with total income from operations at ₹4,767 million and net profit after tax at ₹1,026 million. The company's basic and diluted earnings per share stood at ₹44.55 for the quarter. The results were reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on April 28, 2026. The financial results have been prepared in accordance with Indian Accounting Standards (Ind AS) and are available on the company's website and stock exchange platforms.

*this image is generated using AI for illustrative purposes only.
Sanofi India Limited has announced its financial results for the quarter ended March 31, 2026, reporting total income from operations of ₹4,767 million for the period. The company's net profit after tax stood at ₹1,026 million, while net profit before tax reached ₹1,379 million. The basic and diluted earnings per share for the quarter were recorded at ₹44.55 each, based on a face value of ₹10 per share.
Financial Performance Summary
The company's total comprehensive income for the quarter ended March 31, 2026, was ₹1,026 million. Equity share capital remained constant at ₹230 million across all reported periods. The reserves (excluding revaluation reserve) as shown in the audited balance sheet of the previous year stood at ₹7,262 million for the year ended December 31, 2025.
Comparative Performance
When compared with the previous quarter ended December 31, 2025, Sanofi India showed improvement in several key metrics. Total income from operations increased from ₹4,226 million in Q3 FY26 to ₹4,767 million in Q4 FY26. Net profit after tax also rose from ₹617 million to ₹1,026 million during the same period. However, compared with the corresponding quarter of the previous year ended March 31, 2025, total income declined from ₹5,392 million, while net profit after tax decreased from ₹1,195 million.
Key Financial Metrics
| Particulars | Quarter ended 31.03.2026 (Unaudited) | Quarter ended 31.12.2025 (Unaudited) | Quarter ended 31.03.2025 (Unaudited) | Year ended 31.12.2025 (Audited) |
|---|---|---|---|---|
| Total income from operations | ₹4,767 | ₹4,226 | ₹5,392 | ₹18,571 |
| Net Profit before Tax | ₹1,379 | ₹830 | ₹1,653 | ₹4,720 |
| Net Profit after Tax | ₹1,026 | ₹617 | ₹1,195 | ₹3,267 |
| Total Comprehensive Income | ₹1,026 | ₹634 | ₹1,195 | ₹3,284 |
| Basic EPS (₹) | 44.55 | 26.79 | 51.89 | 141.85 |
| Diluted EPS (₹) | 44.55 | 26.79 | 51.89 | 141.85 |
The financial results for the quarter ended March 31, 2026, have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on April 28, 2026. The results have been prepared in accordance with recognition and measurement principles laid down in the applicable Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act, 2013, read together with Rule 3 of the Companies (Indian Accounting Standards) Rules, 2015, and other accounting principles generally accepted in India.
Historical Stock Returns for Sanofi
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -0.99% | -4.16% | +7.65% | -27.66% | -43.36% | -54.37% |
What strategic initiatives will Sanofi India implement to reverse the declining quarterly revenue trend in FY27?
How might the company's reduced profitability impact its R&D investments and new drug pipeline development?
Will Sanofi India consider portfolio restructuring or market expansion to compensate for the revenue decline?


































